Welcome to our dedicated page for Clearside Biomed SEC filings (Ticker: CLSD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode a biotech filing packed with clinical data and regulatory jargon is tough—especially when Clearside Biomedical’s future hinges on each trial update and capital raise. Our SEC Filings hub tackles that problem head-on. Whether you’re scanning for Clearside Biomedical insider trading Form 4 transactions or need the fine print on a licensing deal buried in an 8-K material events explained report, Stock Titan’s AI spots what moves the stock and summarizes it in plain English.
Every document—from the Clearside Biomedical annual report 10-K simplified to the latest quarterly earnings report 10-Q filing—lands here seconds after it appears on EDGAR. Our platform automatically extracts R&D spend, cash runway, and clinical milestone disclosures, so you can focus on the implications, not the page count. Curious about executive sentiment? Get Clearside Biomedical executive stock transactions Form 4 with real-time alerts and trend graphs. Want a quick readout of last night’s financing? Check the shelf registration S-3 summary our AI generated while you slept.
Use cases professionals rely on daily:
- Compare trial expense trends quarter-over-quarter with our Clearside Biomedical earnings report filing analysis.
- Receive push notifications for Clearside Biomedical Form 4 insider transactions real-time before the market digests them.
- Skip to key risk-factor changes using “understanding Clearside Biomedical SEC documents with AI.�
- Review board pay details pulled from the latest Clearside Biomedical proxy statement executive compensation.
No more sifting through PDFs—our expert, AI-powered summaries turn hundreds of pages into actionable insights, updated the moment Clearside files.
Clearside Biomedical (CLSD) reported cash and cash equivalents of $9.4 million as of June 30, 2025 and total assets of $15.3 million, against total liabilities of $64.1 million, driven largely by a $55.7 million liability related to the sale of future royalties. The company recorded a $12.7 million net loss for the six months ended June 30, 2025 and an accumulated deficit of $368.0 million. License and other revenue for the six months was $2.8 million, including a $1.5 million milestone from Arctic Vision.
In July 2025 the company initiated a formal strategic review and retained Piper Sandler, paused internal R&D and implemented a workforce reduction, estimating third-quarter severance charges of approximately $2.6 million. Management states that, based on current plans, cash on hand is insufficient to fund operations for the next 12 months, and the company disclosed substantial doubt about its ability to continue as a going concern. The company also failed to regain Nasdaq's $1.00 minimum bid requirement and expects a delisting notice, while seeking stockholder approval for a possible reverse split.
Clearside Biomedical (CLSD) has called a 29 Aug 2025 Special Meeting to vote on one item: authorising its Board, within the next 12 months, to implement a reverse stock split at any ratio from 1-for-5 to 1-for-15 and to cut authorised common shares proportionally. The move is designed to lift the share price above Nasdaq’s $1.00 bid-price minimum after CLSD received a non-compliance notice on 7 Feb 2025; delisting could occur after 6 Aug 2025 if the price is not restored. A split would shrink the 78.5 M shares outstanding to 15.7 M�5.2 M and trim authorised shares from 400 M to 80 M�26.7 M. Fractional interests will be cashed out. Brokers may vote uninstructed street-name shares because the proposal is deemed “routine,� so only a simple majority of votes cast is required. Ownership percentages, rights and par value ($0.001) remain unchanged, while equity plan reserves and option exercise prices adjust mechanically. The Board can abandon the action if market conditions improve. Management warns that liquidity might fall, odd lots may form and the post-split price is not guaranteed, but believes maintaining the Nasdaq listing and investor visibility outweigh those risks. Record date: 28 Jul 2025.
FAQ
What is the current stock price of Clearside Biomed (CLSD)?
What is the market cap of Clearside Biomed (CLSD)?
